

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application. Claims indicated as previously added were added by Preliminary Amendment filed February 28, 2002. Amendments to claims submitted herein are fully supported by the specification, therefore no new matter is added by these Amendments.

Listing of Claims

26. (previously presented) A method for treating atherosclerosis in a human or animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

27. (currently amended) A method for treating tumors in a human or animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the tumors are selected from solid tumors, benign tumors, or metastatic tumors.

28. (currently amended) The method of Claim 27, wherein the tumors [comprise] are solid tumors.

29. (currently amended) The method of Claim 27, wherein the tumors are benign tumors.

30. (currently amended) The method of Claim 27, wherein the tumors are metastatic tumors.

31. (currently amended) The method of Claim 29, wherein the benign tumors are selected from hemangiomas, acoustic neuromas, neurofibromas, trachomas, or pyogenic granulomas.

32. (currently amended) A method for treating nerve cell diseases [characterized by undesirable angiogenesis] in a human or animal comprising administering to the human or animal with the nerve cell disease a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the nerve cell disease is selected from acoustic neuroma or neurofibroma.

33. (cancelled)

34. (currently amended) A method for treating diseases of the eye [characterized by undesirable angiogenesis] in a human or animal comprising administering to the human or animal with a disease of the eye with a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the disease of the eye is selected from trachomas, retinopathy of prematurity, diabetic retinopathy, retrobulbar fibroplastic, macular degeneration, corneal graft rejection or neovascular glaucoma.

35. (cancelled)

36. (currently amended) A method for treating inflammation in a human or animal comprising administering to the human or animal with inflammation a composition comprising an angiogenesis-inhibiting amount of 2-methoxyestradiol.

37. (previously presented) The method of Claim 36, wherein the inflammation is associated with pyogenic granulomas, vascular malfunctions, abnormal

wound healing, inflammatory disorders, gout, gouty arthritis, rheumatoid arthritis, psoriasis or immune disorders.

38. (previously presented) A method for treating Behcet's syndrome in a human comprising administering to the human with Behcet's syndrome a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

39. (previously presented) A method for treating Osler-Weber syndrome in a human comprising administering to the human with Osler-Weber syndrome a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

40. (currently amended) A method of treating undesired angiogenesis associated with [complications arising from the female reproductive system] ovulation, implantation of a blastula, or menstruation in a human or animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount to 2-methoxyestradiol.

41. (cancelled)

42. (cancelled)